NCT00581997View on ClinicalTrials.gov

QAX576 in Patients With Pulmonary Fibrosis Secondary to Systemic Sclerosis

PHASE2TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

April 30, 2009

Conditions
Pulmonary Fibrosis Secondary to Systemic Sclerosis
Interventions
DRUG

QAX576

DRUG

Placebo

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY